Experienced in Undifferentiated Pleomorphic Sarcoma

Dr. John H. Strickler

Oncology
Duke Health
Duke Health Integrated Practice Inc
20 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Experienced in Undifferentiated Pleomorphic Sarcoma
Duke Health
Duke Health Integrated Practice Inc
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Strickler is an Oncologist in Durham, North Carolina. Dr. Strickler is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Ampullary Cancer, and Familial Colorectal Cancer. Dr. Strickler is currently accepting new patients.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Call: 919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Enrollment Status: Active_not_recruiting
Publish Date: December 11, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Study Phase: Phase 2
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drugs: ETC-1922159, Pembrolizumab
Study Phase: Phase 1
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
Enrollment Status: Withdrawn
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Panitumumab, Regorafenib, Trifluridine, Tipiracil
Study Phase: Phase 2
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Enrollment Status: Unknown
Publish Date: February 21, 2024
Intervention Type: Other, Drug
Study Drug: Pemigatinib
Study Phase: Phase 2
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Savolitinib
Study Phase: Phase 2
Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer
Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: February 12, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

105 Total Publications

Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression.
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
View All 105 Publications
Similar Doctors
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. Richard F. Riedel
Oncology
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. Richard F. Riedel
Oncology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Juneko E. Grilley-Olson
Hematology Oncology | Hematology | Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Juneko E. Grilley-Olson
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Juneko Grilley-Olson is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Grilley-Olson is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Fibrosarcoma. Dr. Grilley-Olson is currently accepting new patients.

Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology
Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (0.3 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Crawford is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Crawford is currently accepting new patients.

VIEW MORE UNDIFFERENTIATED PLEOMORPHIC SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Strickler's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Strickler is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Distinguished
  • Ampullary Cancer
    Dr. Strickler is
    Distinguished
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Strickler is
    Distinguished
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Familial Colorectal Cancer
    Dr. Strickler is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Strickler is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Lynch Syndrome
    Dr. Strickler is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
  • Neuroendocrine Tumor
    Dr. Strickler is
    Distinguished
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
View All 8 Distinguished Conditions
  • Advanced
  • Appendix Cancer
    Dr. Strickler is
    Advanced
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Esophageal Cancer
    Dr. Strickler is
    Advanced
    . Learn about Esophageal Cancer.
    See more Esophageal Cancer experts
  • Gallbladder Cancer
    Dr. Strickler is
    Advanced
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Gastroesophageal Junction Cancer
    Dr. Strickler is
    Advanced
    . Learn about Gastroesophageal Junction Cancer.
    See more Gastroesophageal Junction Cancer experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Strickler is
    Advanced
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Pancreatoblastoma
    Dr. Strickler is
    Advanced
    . Learn about Pancreatoblastoma.
    See more Pancreatoblastoma experts
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Strickler is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Anal Cancer
    Dr. Strickler is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Anaplastic Thyroid Cancer
    Dr. Strickler is
    Experienced
    . Learn about Anaplastic Thyroid Cancer.
    See more Anaplastic Thyroid Cancer experts
  • Bone Tumor
    Dr. Strickler is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Breast Cancer
    Dr. Strickler is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Carcinoid Syndrome
    Dr. Strickler is
    Experienced
    . Learn about Carcinoid Syndrome.
    See more Carcinoid Syndrome experts
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.